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Aim: To assess the relationship between genotype and neurological progression in 
Ataxia Telangiectasia (A-T). 
Methods: Clinical and laboratory data were extracted retrospectively from the 
records of patients attending the UK National A-T Clinic. Neurological assessments 
were performed using the A-T Index (Crawford Score) and the A-T Neurological 
Examination Scale Toolkit (A-T NEST). Variables influencing phenotype were 
identified by backward elimination mixed-effects linear modelling. Per-individual 
progression was assessed for patients with three or more clinic attendances. 
Results: The genotype could be determined for 125/135 patients. Crawford and A-T 
NEST scores were well correlated (R2=0.675). The best-fitting model for both scoring 
systems contained positive interactions between age and kinase activity (p <1x10-7 in 
both cases) but not protein expression (p = 0.1245 and 0.3938 respectively). Unlike 
the per-genotype analysis, the individual progression of neurological scores in the 34 
patients that attended on three or more occasions was not smooth and linear (and in 
some cases improved over time).  
Interpretation: Residual kinase activity confers a milder phenotype, and there is no 
difference in phenotype between kinase-dead and protein-null genotypes. The non-
linear progression of individual patients’ neurological scores may reflect biological 
complexity, day to day variability, limitations of the assessment methods or a 
combination of all of three.  
 
Shortened title 
Longitudinal analysis of Ataxia Telangiectasia 
What this paper adds 
 The A-T NEST scoring system is well correlated with the validated  A-T Index 
 The longitudinal progression of neurological scores in individual patients is 
typically not smooth and linear.   
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Ataxia Telangiectasia (A-T) is an incurable autosomal recessive condition associated 
with the loss of ATM function. Incidence is estimated to be 1:300,000 live births in 
the UK1,2. The clinical features include neurological disability from progressive 
movement disorders, dystonia, ataxia, oculomotor abnormalities, communication 
difficulties, immunodeficiencies and increased cancer susceptibility; other systemic 
associations include chronic respiratory disease, growth retardation, and diabetes 
mellitus3.  The median life expectancy of A-T patients is 19-25 years4. 
 
ATM is a serine/threonine kinase involved in DNA double-strand break (DSB) repair 
and cell cycle arrest3. There are over 450 documented mutations in the ATM gene 
that have been associated with A-T, most of which are truncating mutations (Human 
Gene Mutation Database5). This is significant as the kinase domain is close to the C-
terminus, so truncating mutations are likely to result in loss of ATM kinase activity. 
Classical A-T is associated with the absence of ATM kinase activity and a severe 
phenotype, but the severity of A-T shows a wide degree of variation6. The presence 
of residual kinase activity is associated with later onset disease, with a milder 
neurological phenotype and fewer systemic features7. Of the patients with Classical 
A-T, some have no detectable ATM protein, whereas others express a kinase-dead 
protein. A cross-sectional study found no difference in neurological severity between 
these two groups, but that the kinase-dead genotype does have better 
immunological features7. However the clinical significance of the differences in 
immunological profile is uncertain, particularly as the immunological component of 
the disease is not progressive8. Finally, whilst neurological impairment is worse in 
older Classical patients9  the nature of disease progression is currently unclear as no 
longitudinal studies have been published.        
 
Two scoring systems have been developed specifically for the assessment of the 
neurological features of A-T. The first of these, the A-T Index (Crawford Score), 
consists of a 39 point scale derived from 10 items9. The A-T Neurological Examination 
Scale Toolkit (A-T NEST) is a more comprehensive assessment, comprising 64 items 
of which 53 are purely neurological, and also has a communication domain. Both 
scales are used to assess patients that attend the National A-T Clinic, a multi-
disciplinary clinic for patients with A-T or A-T-like disorders (ataxia telangiectasia-like 
disorder and ataxia with oculomotor apraxia types 1 and 2), based in Nottingham, 
United Kingdom (UK). It historically saw patients of all ages, but now sees only 
children and young people up to 16 years of age. Adults with A-T are seen in a 
Specialist Clinic in Papworth Hospital, Cambridgeshire, UK. 
 
In this paper, a series of patients from this clinic is presented with investigations of 
genotype-phenotype correlations. The series is considerably larger than those 
previously published and for the first time includes longitudinal analysis of the 




Compilation of the database 
Clinical and laboratory data were collected retrospectively from the medical records 
of patients attending the National A-T Clinic from December 2001 to March 2014. 
Each patient was assigned a unique ID number to allow for the creation of an 
anonymised database (Additional File 1). ATM mutations were identified in all A-T 
patients, by the Taylor laboratory. ATM protein expression was assessed as either 
present (irrespective of the relative amount compared with normal) or absent in 
lymphoblastoid cell lines derived from patients by western blotting. Some cell lines 
expressed a ‘trace’ while others expressed a normal level for one allele. In addition, 
the kinase activity of any ATM protein present was also assessed by the Taylor 
laboratory, as described previously10, using the same patient-derived lymphoblastoid 
cell lines. The types of ATM mutation and whether these are associated with 
retained kinase activity was discussed in Reiman et al, (2011)10 and these same 
criteria have been used to ascribe the presence or absence of activity associated 
with expression of ATM from some common ATM mutations. For the present study 
kinase activity was also scored as either absent (0) or present (1), or left blank where 
the status was unknown. If the protein expression was recorded as absent, the 
kinase activity was also assumed to be absent. Radiosensitivity was scored based on 
the total chromosome damage (number of mainly chromatid gaps, breaks and 
interchanges) scored in whole blood cultures (PHA stimulated T cells) after exposure 
of blood to 1Gy gamma rays (137Cs) 4h before harvest at 72h (cells in G2 phase of the 
cell cycle). 
 
At each visit a neurological assessment was performed using the A-T Index (giving a 
Crawford Score). For visits made after 2006, an additional assessment using the A-T 
NEST (Additional File 2) was performed. To account for slight revisions to the A-T 
NEST as it has been developed, the scores for each domain were calculated as a 
percentage of the maximum for the version used. The total neurological score and 
total score for the A-T NEST were calculated as the weighted average of the relevant 
domain as described in Additional File 2. Where data were missing, this was imputed 
from the non-missing elements.  
Statistical analyses 
For longitudinal regression analysis, mixed linear models were fitted to the data 
using the lme4 package11. A maximum model was specified with Neurological Score 
as the dependent variable and fixed effect terms for age, kinase activity, protein 
expression and sex, fixed effects interaction terms between age and each of the 
other covariates, and random effects for the intercepts, age, kinase activity and 
protein expression of each participant. A backwards elimination approach was then 
used using the lmerTest package12. Q-Q and Tukey-Anscombe plots were created 
from the resulting models to assess for deviances from normality, heteroskedasticity 
and non-linearity. Descriptive longitudinal analyses were performed on patients with 
neurological scores from 3 or more visits. To compare the two main assessors, 
ANCOVA was performed with Neurological Score as the dependent variable, age as 
the dependent variable and the assessors as the covariate. All analyses were 
5 
 
performed using a custom script in the R statistical environment that can be shared 
on request. Plots were generated using the ggplot2 package13. 
 
Ethical considerations 
This was a non-intervention observational study involving retrospective review of 
patients’ medical records. This gave an opportunity for quality control of the 
documentation and reliability of our clinical assessments. This routine clinical review 
is required of our clinical assessments and is an integral part of the clinical service. 
We hoped this would inform and support not only our practice in the UK but also at 
other A-T clinics. Research Ethics Committee approval was not required. 
Results 
Composition of the database 
Of the 144 patients in the database, 135 had a diagnosis of A-T.  68 were male and 
67 female. Genetic analysis was available for 120 (a further 7 patients had only one 
allele characterised). 37 were homozygotes and 83 were compound heterozygotes. 
In total, 140 unique mutations are represented in the database. The median age at 
first presentation was 8 years 6 months, and for all visits was 10 years 1 month, with 
the interquartile ranges 9 years 4 months and 7 years 9 months respectively (Figure 
1B). The molecular phenotype of 125 patients was determined by western blotting 
of patient-derived lymphoblastoid cell lines and/or identification of previously 
characterised mutations. 71 patients had at least some ATM expression however the 
majority of the ATM expressed by these patients was kinase-dead (Figure 1C). In 
total, 56 patients expressed no ATM protein (protein null), 44 expressed some ATM 
protein without kinase active (kinase dead) and 25 had both ATM protein expression 
and kinase activity (kinase active). 34/125 (27.2%) patients had visited the clinic 
three times or more (Figure 1D). Nine neurologists performed at least one of the 
assessments. Of the 92% where the assessor was identifiable from the notes, 85% 
were performed by either WPW or GC.   
Comparison of A-T NEST and A-T Index (Crawford scores) 
A positive correlation was observed between A-T NEST neurological scores and 
Crawford scores performed on the same visit (adjusted R2= 0.675) (Figure 2). The 
gradient of the slope was shallower than would be the case if the two scores were 
perfectly equivalent. Indeed, extrapolation of the regression line reveals that a score 
of 0 on the Crawford score is equivalent to 19.2 on the A-T NEST. This, and the 
spread of data across the regression line, may be a reflection the fact that the A-T 
NEST contains many more items for each domain than the Crawford Score and so is 
more discriminating (Additional File 3). 
Longitudinal genotype-phenotype analysis 
To assess the neurological progression longitudinally a mixed model approach was 
used with random effects accounting for per-individual variation and fixed effects 
based on characteristics of interest. A hypothesis neutral approach was used to 
identify which characteristics significantly affected phenotype. First, a maximum 
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model was created for each neurological scores and the fixed effects coefficients 
plotted (Figure 3A). Then a backwards elimination approach was used to specify 
which coefficients were significant14. Model diagnostic plots generated for the final 
models showed no significant violation of the assumptions required for linear 
modelling (Additional File 4A and 4B). The only random effect that was significant in 
either model was a term for differing intercepts (1|Unique.ID, p <1x10-7 for the 
Crawford Scores and p=0.0011 for A-T NEST). For the Crawford score model, the 
following fixed effect terms were retained: Age (p <1x10-7), Kinase (p=0.357), 
Age:kinase (p <1x10-7). Age:protein was not retained (p= 0.1245) This means the 
intercept of the regression of score on age differs based on unique.ID and kinase 
activity, and the slope is influenced by the kinase activity, but not protein expression 
or sex (Figure 3B).  For A-T NEST scores, the Age (p <1x10-7), Kinase (p=0.1218), 
protein (p=0.0206) and Age:kinase (p <1x10-7) terms were retained but again not 
Age:protein (p=0.3938) (Figure 3C). It should be noted that although some retained 
terms have p values greater than 0.05, when models with and without these terms 
are compared with ANOVA, the p values are highly significant, justifying their 
inclusion. 
Descriptive longitudinal analysis 
Of the 35 patients who had visited the clinic 3 or more times, 33 had at least 3 
Crawford scores (1 had received only an A-T NEST on one occasion, the age of the 
other at the time of assessment could not be determined from the medical notes). 
Strikingly, the majority of patients’ scores did not follow a smooth progression 
(Figure 4A).  This was a feature of all genotype groups. Furthermore it was not 
accounted for by different assessors scoring on different occasions (Additional File 
5). 
 
There were 8 patients who had 3 A-T NEST scores. The progression of A-T NEST 
scores was similar to the Crawford scores for each patient (Figure 4Bl). All of the 
major domains of the A-T NEST (communication, eyes, ataxia, and movement 
disorder) showed considerable variation in trend (Figure 4C). The ataxia and 
movement domains showed the most consistent trend to decrease over time.  In 
cases where the overall score was broadly unchanged across a 5 year series, there 
was much variation in the individual domains (see patients 5442 and 7774 in Figure 
4).  
Discussion 
With 135 patients, our cohort is larger than previous studies of the clinical features 
of A-T7,15. This paper is the first to use a longitudinal approach to compare 125 
patients based on their molecular phenotype and to characterise disease 
progression. 
 
The A-T Index and A-T NEST were used to quantitatively assess neurological 
phenotype. Unlike other ataxia assessments, both these scoring systems are 
designed to capture the specific features associated with A-T. A good correlation was 
found between A-T NEST and Crawford Scores performed on the same day, but we 
speculate the A-T NEST may offer discrimination of a wider range of clinical 
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severities. A further potential benefit of the A-T NEST it that it is more discriminating 
within each domain.  For example, the neuro-ophthalmology of A-T is assessed in the 
A-T Index through a single item with a range of 0-4, whereas the current version of 
the A-T NEST has 15 items and a range of 0-30. A prospective study directly 
comparing the A-T NEST and A-T Index is needed to assess the validity of the above 
speculations.  
 
Mixed model analysis is a well-recognised method of dealing with longitudinal data 
with variable time-intervals and missing data. Consistent with previous reports, we 
found that the disease is, in general, progressive and that the presence of ATM 
kinase activity is associated with a milder phenotype. No significant interaction 
between age and protein expression was found, meaning that there is on average no 
difference in phenotype between the protein null and kinase dead genotypes. 
 
In a preliminary analysis of this database, we were surprised to find a slightly milder 
phenotype in the kinase dead group compared to the protein null16. In that analysis 
biochemical data was available for only 114 patients, rather than the 125 presented 
in this paper. The data for patients over the age of 20 are sparse (in part because the 
founding of the Papworth adult clinic coincided with our study period as so new 
admissions to this service were not included in our cohort). Consequently in the 
original analysis a few data points from older patients were highly influential. The 
inclusion of the additional 11 patients increased the representation within the older 
group and consequently no significant difference between the protein null and 
kinase dead groups remained. 
 
The clinical findings are mirrored in the radiosensitivity of patient derived fresh 
blood lymphocytes. There was no difference between the kinase-dead and protein 
null groups, but there were significantly fewer foci of chromosomal damage in the 
kinase-active patients (Additional File 6). This further supports the idea that the only 
clinically significant role of ATM in A-T is due to its role in DSB repair.  
 
However, there are some noteworthy limitations to even the analysis we present 
here. First, this was a retrospective study and so prone to confounders that we have 
not thought to control for. Next, in the first few years that the clinic was run 
attendances were not at fixed intervals, and even after this remain at the discretion 
of the families, whom often have to travel great distances to attend. Consequently, 
there were relatively few repeated measures for each patient, reducing the accuracy 
of random-effects modelling. Finally, the data is skewed towards the paediatric 
population and so we cannot exclude the possibility of subtle differences in 
adulthood. Future work following patients described in this work into adulthood 
would be valuable.   
 
In addition to the mixed model approach, descriptive analyses were performed. 
Whilst in general neurological scores are worse in older patients, the scores of 
individual patients do not decrease linearly over time. This was true for both of the 
scoring systems used. All of the major domains in the A-T NEST also showed 
considerable variability within patients over time. This non-linearity was seen in all 
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three groups. The key question is whether the neurological features of A-T are 
genuinely fluctuant or have our assessments not captured the true clinical picture? 
Most of the patients are children, so fatigue and emotional state could be important 
confounders (especially so as the data are collected in the context of a day-long 
multidisciplinary clinic). It is also possible that there is significant inter-observer 
variability. This is less likely for three reasons. First the A-T Index has been shown to 
have good inter-observer reliability in most domains9 (a validation study for the A-T 
NEST is currently in progress). Second, the fluctuations in scores were not associated 
with any particular assessors (Additional File 5). Third, when looking at the whole 
dataset (where the patients were not allocated to specific assessors) there was no 
significant difference in the regression slopes between the two main assessors, WPW 
and GC (Additional File 7, ANCOVA, p=0.509). It seems likely that the non-linear 
progression seen may simply be due to their day to day and hour to hour variation 
associated with fatigue and fluctuations in mood, which are commonly reported by 
parents / guardians. However until we have completed the inter-observer validation 
of the A-T NEST, and the non-linear progression of the neurological function is better 
understood, we will continue to use both in clinical assessments, with the addition of 
a parent / guardian score of the child’s fatigue/performance at the time of testing.  
 
Ultimately, determining the natural history of A-T through longitudinal studies is 
important to be able to provide education to patients and their families as well as 
potentially helping understand the pathophysiology of the disease. Despite this 
paper being the largest study of the clinical features of A-T, a still-larger dataset with 
more visits for each patient and assessment of other systems affected by the disease 
would be necessary to produce such a robust predictive model. This may be possible 
in future as existing patients are now invited for bi-annual follow-up and an 
international collaboration to create a shared registry of patient data has been 
muted. However our work clearly highlights the need for a critical evaluation of the 
assessment tools currently used, in addition to multi-centre collaboration to better 
characterise the disease.   
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Figure legends 
Figure 1: Summary of patient demographics and biochemistry 
A) Summary of gender breakdown and mutational status. 
B) Histogram of the age of the patients at the time of assessment. Blue = only the 
first assessments, Red = all assessments. Box represents the inter-quartile range. 
C) ATM protein expression and kinase activity of lymphoblast derived cell lines was 
calculated relative to wild-type. Red line= total number of patients, black line = 
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number of patients with protein abundance data. The table summarises the number 
of patients in each group used subsequently for genotype-phenotype analyses. 
D) Distribution of the number of visits made by the patients. 
Figure 2: Correlation between A-T NEST and Crawford scores 
Scatter plot of A-T NEST and Crawford scores, where both were performed at the 
same visit. Blue line = regression line, grey area = 95% confidence interval for this 
line, red lines = 95% prediction interval for the data.  
Figure 3: Mixed linear model analysis of the longitudinal progression 
of Crawford and A-T NEST scores. 
A) Estimated fixed effects coefficients for each variable in the Maximum models for 
A-T NEST and Crawford scores (with the exception of the Intercept). Line represents 
2 standard deviations either side of the estimated coefficients. Lines coloured red 
were retained as significant in a backwards elimination approach. 
B) Crawford Scores plotted against age, with lines representing fixed effects from the 
minimal model generated by backwards elimination. 
C) As for B) but for the A-T NEST Scores.  
Figure 4: Descriptive longitudinal analysis of Crawford Scores and A-
T NEST scores 
A) Neurological score for patients who had been assessed using the A-T Index on 3 or 
more occasions plotted against age. 
B) The Crawford and A-T NEST scores for patients who had received 3 A-T NEST 
assessments plotted against age. 
C) The relationship between age and scores in each of the major domains of the A-T 
NEST plotted for the 8 patients that had been assessed on 3 occasions.  
Additional File 1 
An anonymised version of the database used for the analyses within this paper. 
Additional File 2 
The current edition of the A-T NEST pro forma and instructions. 
Additional File 3 
For each visit where both an A-T NEST and A-T Index assessment were performed, 
the domain score for oculomotor abnormalities (top left) and gait/ataxia (top right) 
are plotted. The Crawford compound ataxia score is the sum of the gait, sitting and 
standing posture sections of the A-T Index and is comparable to the features 
assessed in the A-T NEST ataxia domain. 
Additional Files 4A and 4B 
Diagnostic plots for the mixed models. Q-Q plots for normality for both the random 
effect. Q-Q plot for the fitted residuals from the fixed effect model. Tukey Anscombe 




Additional File 5 
The data as described in Figure 4, but with the assessors for each visit indicated 
Additional File 6 
A plot of the radiosensitivity as determined by total chromosomal damage scored in 
patient derived whole blood cultures after exposure to 1Gy 4h prior to harvest, for 
each molecular phenotype, Box plot is of median and quartiles, with raw data 
overlayed. There is a significant difference between the kinase dead and kinase 
active groups (p= 3.757x10-9, student t-test), but no difference between kinase dead 
and protein null groups (p=0.343) 
Additional File 7 
All A-T NEST assessments performed by GC and WPW are plotted against age. Blue = 
GC, Orange = WPW. Grey region = 95% confidence interval for regression lines. There 
is no significant difference between the regression slopes (p=0.509). 
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